”A drug like Darzalex only comes along once every 20 years”
Genmab’s CEO is ecstatic over the biotech's “shining star”, bone marrow cancer drug Darzalex. He doubts he will see anything like it in his time in the company, but is working intently on finding a new cash cow.
BY LOUISE WENDT JENSEN
"It's highly unusual, and the good thing is that it doesn’t stop here," Genmab CEO Jan van de Winkel says about the cancer treatment Darzalex, which is on course to reach more than USD 1 billion in global sales in its second year on the market, earning it so-called blockbuster status.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Darzalex moves closer to expanded EU approval
For abonnenter
Genmab raises guidance ahead of annual report
For abonnenter
Genmab digs deeper in its goldmine
For abonnenter
